KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) Equity Average: 2014-2025

Historic Equity Average for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Sep 2025 value amounting to $350.5 million.

  • Aurinia Pharmaceuticals' Equity Average fell 6.85% to $350.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $350.5 million, marking a year-over-year decrease of 6.85%. This contributed to the annual value of $377.7 million for FY2024, which is 3.57% down from last year.
  • Aurinia Pharmaceuticals' Equity Average amounted to $350.5 million in Q3 2025, which was up 2.27% from $342.7 million recorded in Q2 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' Equity Average peaked at $463.6 million during Q1 2022, and registered a low of $315.2 million during Q3 2021.
  • In the last 3 years, Aurinia Pharmaceuticals' Equity Average had a median value of $376.3 million in 2024 and averaged $373.9 million.
  • In the last 5 years, Aurinia Pharmaceuticals' Equity Average surged by 39.81% in 2021 and then dropped by 14.17% in 2023.
  • Over the past 5 years, Aurinia Pharmaceuticals' Equity Average (Quarterly) stood at $388.6 million in 2021, then increased by 6.64% to $414.4 million in 2022, then dropped by 7.12% to $384.9 million in 2023, then declined by 0.57% to $382.7 million in 2024, then decreased by 6.85% to $350.5 million in 2025.
  • Its last three reported values are $350.5 million in Q3 2025, $342.7 million for Q2 2025, and $363.8 million during Q1 2025.